radioresistance 11 and chemoresistance 12,13 of the GBM cells, which results from the genetic transformation and tumour heterogeneity, have made them refractory to conventional therapies. Recently, combination of temozolomide (TMZ, a DNA alkylating agent) + radiotherapy (RT) has improved the therapeutic outcome with limited survival benefit. 14 The median overall survival (OS) was 14.6 months for RT/TMZ compared to the OS of 12.1 months for RT alone. Moreover, epigenetic silencing of the DNA repairing gene is a prerequisite for the success of this approach 15 which, in turn, requires postoperative local chemotherapy of limited utility. 16 Overall, the shortcomings of current therapeutic strategies highlight the need for effective and generic multimodal therapeutic strategies.
Recently, the application of nanomedicine for GBM therapy has emerged as a promising alternative that can overcome the hurdles of the conventional therapies. 17 Among the various types of systems that have been used for GBM therapy, gold NPs (AuNPs) appeared to be the most appealing nanosystem because of their biocompatibility, small size, easy synthesis, tunable surface functionalities and enhanced CT and MRI contrast capabilities. 18, 19 By using antibody tagged gold nanoshells, Bernardi et To address these challenges, we developed a multifunctional generic nanomedicine for combined chemo-radiotherapy of GBM.
This strategy takes advantage of higher penetrating capacity of ionizing radiation compared to that of NIR, which is needed for brain cancer therapy in human patients. Critically, we used patient derived cell lines that were derived using serum free cell derivation technology, so that our therapeutic approach could be tested against evolving and drug resistant tumors.
At first, using PEI (Polyethylenimine, a positively charged polymer) capped AuNPs (AuNPs-PEI) we confirmed that even after highly improved intracellular (nuclear and cytosolic) delivery
AuNPs alone cannot radiosensitise patient derived GBM cells adequately.
Thereafter, we developed a multifunctional nanosphere that comprises AuNPs surface engineered with the anticancer drug cisplatin (AuNPs-Pt) (Fig. 1 ). The nanosphere demonstrated 
X-ray photoelectron spectroscopy
The elemental composition of the nanoconjugates was characterized by XPS analysis using K-Alpha XPS spectrometer (Thermo, UK).
Cell uptake studies
S2 cells were seeded on 13 mm ECM coated glass coverslips placed inside 24-well tissue-culture plate at seeding density of 6 x10 Thrice washed cells were stained with Alexa-488 conjugated secondary antibody (1:500, Invitrogen) for 2 h at room temperature.
The nucleus was counterstained with DAPI (Sigma). Cellular localization of the nanoconjugates was viewed using dark-field confocal microscopy (Leica BMI 6000B) and quantified using Imaris 7.4.2 software. Images were processed using ImageJ software.
MTS cell viability assay
MTS assay was performed to analyze the inherent toxicity of 
Differential interference contrast (DIC) microscopy
The effect of AuNPs-PEI treatment on S2 cell morphology, which represents the cytotoxicity of the nanoconjugates, was imaged using DIC microscope (Nikon, U.S.A.). Image analysis was performed with Imaris 7.4.2 (γH2AX) and ImageJ (caspase) software.
γH2AX and

Growth curve analysis
GBM cells were seeded at a density of 750×10 3 cells/T75 tissue culture flask pre-coated with ECM and incubated overnight. the extent of uptake of AuNP-MUA and AuNP-Pt was comparable (Fig. 5a , b, c) we observed activation of γH2AX foci only in the AuNP-Pt treated cells (Fig. 6a, b, c) . This observation indicates that the nanosphere could deliver sufficient amount of cisplatin into the cell through endocytosis. 45 At the acidic pH of the late endosome the bond between cisplatin and AuNPs was broken. 31 The active and free cisplatin molecules (M.W 300D, which corresponds to < 1 nm size) diffused out of the endosomal compartment, passed through the nuclear pore and reached the DNA resulting in DNA damage. 41 At day 4, we observed further increase in the cellular internalization of the AuNP-MUA and AuNP-Pt (Fig. 5a, d, e) . Eventually, AuNP-Pt treatment led to the activation of caspase-3 (Fig. 6a, d , e), which decreased cell growth rate significantly, unlike AuNP-MUA treated cells (Fig. 6f) . In the next step, we evaluated the synergistic chemoradiotherapeutic potential of this nanosphere using S2 cells. After irradiation at day 4, compared to the RT or AuNP-MUA + RT, the AuNP-Pt + RT group showed significant enhancement in the DNA double strand break as indicated by the increased density of γH2AX foci (Fig. 7a, b, c) . This increased DNA damage led to enhanced activation of caspase-3, resulting in significant improvement in the rate of apoptosis (Fig. 7a, d, e) . Growth curve analysis (Fig. 7f) showed that, until day 20, RT and AuNP-MUA + RT caused similar decreases in the cell growth rate. Beyond this time-point, the AuNP- 23 On the contrary, the probability of photoelectrons and Auger electrons production through photoelectric effect is lesser at MeV energy range compared to KeV energy. 49 Therefore, for clinical application of this technology use of new generation Linacs (Linear accelerator, source of MeV energy), which are flattening filter free and thus can increase the radiation dose deposition rate, would be necessary.
Second, to ensure optimal cell uptake of the nanosphere, which is a prerequisite to achieve maximum efficacy of any therapeutics, we selected 50 nm sized AuNPs. 50 However, for in vivo application of this technology, the size of the nanomedicine should be restricted to ~ 6 nm that is the upper limit of safe renal clearance. 51 This modification will require the use of smaller sized AuNPs with proper surface chemistry that can overcome toxicity concern related to long-term accumulation NPs in the body. 52, 31 In this context, the recent findings of Miladi et al. demonstrating radiosensitizing potential of ultrasmall Au@DTDTPA suitable for renal clearance holds significant importance. 52, 19 This ultrasmall nanosystem was also tractable by high resolution MRI, which helped to optimize RT schedule in vivo. Therefore, it will be rational to develop cisplatin conjugated magnetic core-gold shell nanosphere that can be visualized by MRI and will have a appropriate size and surface chemistry for optimal biodistribution and renal clearance.
Conclusion
In summary, we report the proof-of-concept for the strategy to develop a generic nanomedicine suitable for multimodal therapeutic targeting of challenging cancers such as GBM. Using patient derived treatment resistant cells, we have established that AuNP-Pt-mediated concomitant chemo-radiotherapy is a potential therapeutic modality that can overcome the limitations of standard treatment.
Vehiculation of cisplatin using AuNP will modify the pharmacokinetics of this drug resulting in a significant decrease in cisplatin-induced systemic toxicity. 31 By combining this new approach with cancer cell-targeting probes, a tumour targeted 'theranostics' can be developed in the future. 53 This will provide a more tractable, specific and efficient therapeutic strategy for treatment of GBM and other challenging cancers.
